Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) is scheduled to be announcing its earnings results after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of C($0.20) per share for the quarter.
Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last posted its earnings results on Tuesday, May 14th. The company reported C($0.21) earnings per share for the quarter, hitting the Zacks’ consensus estimate of C($0.21). The firm had revenue of C$0.04 million for the quarter, compared to the consensus estimate of C$0.07 million.
Aurinia Pharmaceuticals stock traded up C$0.05 during midday trading on Monday, reaching C$8.43. 24,500 shares of the stock were exchanged, compared to its average volume of 58,344. The firm has a fifty day simple moving average of C$8.32. The company has a current ratio of 23.31, a quick ratio of 22.28 and a debt-to-equity ratio of 0.30. The stock has a market cap of $773.82 million and a price-to-earnings ratio of -11.91. Aurinia Pharmaceuticals has a 52 week low of C$6.61 and a 52 week high of C$10.47.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Recommended Story: Fibonacci Channel
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.